Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention

• Autores: Nocera, Nadia F.; Lee, M. Catherine; De La Cruz, Lucy M.; Rosemblit, Cinthia; Czerniecki, Brian J.
• Año de publicación: 2016
• Idioma: inglés
• Tipo de recurso: artículo
• Materia: BREAST CANCER; CANCER VACCINES; HER2; IMMUNOTHERAPY; TH1 IMMUNITY
• Institución: Consejo Nacional de Investigaciones Científicas y Técnicas

The ErbB/B2 (HER-2/neu) oncogene family plays a critical role in the development and metastatic spread of several tumor types including breast, ovarian and gastric cancer. In breast cancer, HER-2/neu is expressed in early disease development in a large percentage of DCIS lesions and its expression is associated with an increased risk of invasion and recurrence. Targeting HER-2 with antibodies such as trastuzumab or pertuzumab has improved survival, but patients with more extensive disease may develop resistance to therapy. Interestingly, response to HER-2 targeted therapies correlates with presence of immune response genes in the breast. Th1 cell production of the cytokines interferon gamma (IFNγ) and TNFα can enhance MHC class I expression, PD-L1 expression, augment apoptosis and tumor senescence, and enhances growth inhibition of many anti-breast cancer agents, including anti-estrogens and HER-2 targeted therapies. Recently, we have identified that a loss of anti-HER-2 CD4 Th1 in peripheral blood occurs during breast tumorigenesis and is dramatically diminished, even in Stage I breast cancers. The loss of anti-HER-2 Th1 response is specific and not readily reversed by standard therapies. In fact, this loss of anti-HER-2 Th1 response in peripheral blood correlates with lack of complete response to neoadjuvant therapy and diminished disease-free survival. This defect can be restored with HER-2 vaccinations in both DCIS and IBC. Correcting the anti-HER-2 Th1 response may have significant impact in improving response to HER-2 targeted therapies. Development of immune monitoring systems for anti-HER-2 Th1 to identify patients at risk for recurrence could be critical to improving outcomes, since the anti-HER-2 Th1 response can be restored by vaccination. Correction of the cellular immune response against HER-2 may prevent recurrence in high-risk patients with DCIS and IBC at risk of developing new or recurrent breast cancer.
Fil: Nocera, Nadia F.. University of Pennsylvania; Estados Unidos
Fil: Lee, M. Catherine. H. Lee Moffitt Cancer Center; Estados Unidos
Fil: De La Cruz, Lucy M.. University of Pennsylvania; Estados Unidos
Fil: Rosemblit, Cinthia. University of Pennsylvania; Estados Unidos
Fil: Czerniecki, Brian J.. H. Lee Moffitt Cancer Center; Estados Unidos